Investor
Pfizer Inc
CIK 0000078003 · filed 2026-02-12 · SEC filing
13F book
$236.5M
Positions
18
Largest name
18.6%
Oric Pharmaceuticals, Inc. · ORIC
Est. mark
—
Need a prior quarter to estimate
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Oric Pharmaceuticals, Inc. | ORIC | 5.38M | $44M | 18.6% | — | Held |
| Arvinas, Inc. | ARVN | 3.46M | $41M | 17.3% | — | Held |
| Celcuity Inc. | CELC | 349.4K | $34.8M | 14.7% | — | Held |
| Wave Life Sciences Ltd. | WVE | 1.88M | $31.9M | 13.5% | — | Held |
| Allogene Therapeutics, Inc. | ALLO | 22M | $30.2M | 12.8% | — | Held |
| Zura Bio Ltd | ZURA | 2.97M | $15.6M | 6.6% | — | Held |
| Pyxis Oncology, Inc. | PYXS | 7.03M | $8.09M | 3.4% | — | Held |
| Caribou Biosciences, Inc. | CRBU | 4.69M | $7.46M | 3.2% | — | Held |
| Cardiff Oncology, Inc. | CRDF | 2.41M | $6.78M | 2.9% | — | Held |
| Biohaven Ltd. | BHVN | 505.6K | $5.71M | 2.4% | — | Held |
| Spero Therapeutics, Inc. | SPRO | 2.36M | $5.5M | 2.3% | — | Held |
| NextCure, Inc. | NXTC | 157.6K | $2.24M | 0.9% | — | Held |
| Zentalis Pharmaceuticals, Inc. | ZNTL | 953.8K | $1.29M | 0.5% | — | Held |
| Q32 Bio Inc. | QTTB | 277.8K | $922.2K | 0.4% | — | Held |
| AN2 Therapeutics, Inc. | ANTX | 715.3K | $815.4K | 0.3% | — | Held |
| Bolt Biotherapeutics, Inc. | BOLT | 31.3K | $171.2K | 0.1% | — | Held |
| Ginkgo Bioworks Holdings Inc | — | 2.93K | $24.3K | 0.0% | — | Held |
| Senseonics Hldgs Inc | — | 2.17K | $12K | 0.0% | — | Held |
Positions as of Q4 2025. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.